RxLibra

Search Generic Medicine

Medicine Index

Search by generic name

Generic Larotrectinib

Larotrectinib is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncology in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbour neurotrophic receptor tyrosine kinase (NTRK) gene fusions.

In November 2018 larotrectinib received its first global approval in the USA for the treatment of adult and paediatric patients with solid tumours that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. 

Larotrectinib sold as brand names VITRAKVI,It has a generic form of several brands.


 

Laronib 100

Brand Name : Laronib
Composition : Larotrectinib 100mg
Indication: Antineoplastic- Tropomyosin Receptor Kinase (TRK) Inhibitor
Form : Capsule (Oral administration)
Packing : 30 Capsules in 1 box
Manufactured By:Everest Pharma [Bangladesh]
Storage:Store at room temperature (10-30°C)

Laronib 25

Brand Name : Laronib
Composition : Larotrectinib 25mg
Indication: Antineoplastic- Tropomyosin Receptor Kinase (TRK) Inhibitor
Form : Capsule (Oral administration)
Packing : 30 Capsules in 1 box
Manufactured By:Everest Pharma [Bangladesh]
Storage:Store at room temperature (10-30°C)

Lotenib 100

Brand Name : Lotenib
Composition : Larotrectinib 100mg
Indication: Antineoplastic- Tropomyosin Receptor Kinase (TRK) Inhibitor
Form : Capsule (Oral administration)
Packing : 30 Capsules in 1 box
Manufactured By: DRUG INTERNATIONAL Ltd[Bangladesh]
Storage:Store at room temperature (10-30°C)


Larotrectinib :Select patients for treatment with this drug based on the presence of a NTRK gene fusion in tumor specimens.

Usual Adult Dose for Solid Tumors:

  • Body surface area least 1 m2:
    100 mg orally 2 times a day until disease progression or unacceptable toxicity

Use: For the treatment of adult patients with solid tumors that:

  • Have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation
  • Are metastatic or where surgical resection is likely to result in severe morbidity
  • Have no satisfactory alternative treatments or that have progressed following treatment

Usual Pediatric Dose for Solid Tumors:

28 days and older:

  • Body surface area at least 1 m2: 100 mg orally 2 times a day until disease progression or unacceptable toxicity
  • Body surface area less than 1 m2: 100 mg/m2 orally 2 times a day until disease progression or unacceptable toxicity.

Use: For the treatment of pediatric patients with solid tumors that:

  • Have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation
  • Are metastatic or where surgical resection is likely to result in severe morbidity
  • Have no satisfactory alternative treatments or that have progressed following treatment

Larotrectinib Uses:

12 anticancer drugs for treatment Pancreatic Cancer

 

Tags:  

You must be logged in to post a comment.